(R,R)-Palonosetron Hydrochloride

DRUG INTERMEDIATES

Product Details

CAT No.# CS-T-60134
Category Drug Intermediates
CAS 135729-75-8
Molecular Weight 332.87
Molecular Formula C19H25ClN2O
Stock Status: In-Stock
Purity: >98%
Melting Point: >300
Solubility: DMSO, Methanol, Water
Appearance: Off-White Solid
Synonyms: (R,R)-Palonosetron Hydrochloride; (3aR)-2-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one Hydrochloride;
Application Notes: Serotonin 5-HT3 receptor antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). Antiemetic.
References: Clark, R.D., et al.: J. Med. Chem., 36, 2645 (1993), Wong, E.H.F., et al.: Br. J. Pharmacol., 114, 851 (1995), Grunberg, S.M., et al.: Expert. Opin. Pharmacother., 4, 2297 (2003), Eisenberg, P., et al.: Ann. Oncol., 15, 330 (2004), Siddiqui, M.A.A., et al
Storage: For long term store at -20�C
Shipping: Free Shipping for worldwide on order above 2000 USD , Extra charges for Dry ice shipment 80$*
COA / MSDS:    View COA    MSDS
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Benidipine D7
4. Lauroside D
5. Triazolam 13C D3
6. Icatibant impurity 1
7. BISPHENOL AF (RING-13C12)
8. 0.1% TFA in Water ULC-MS
9. Metamizole EP Impurity C HCl
10. Silodosin Metabolite D4
11. Brivaracetam Carboxylic acid metabolite [UCB 42145]
12. Terbuthylazine D5
13. tibolone (848)
14. (Z)-Dimethylvinphos
15. Silodosin Metabolite
16. 2-Phenoxymethanesulfonanilide
17. Nimesulide EP Impurity A
18. Acetone HPLC
19. Nandrolone Decanoate EP impurity F
20. N-(4-Bromophenyl)-3-methyl-N-(m-tolyl)aniline


Smileys:
O=C1N([C@H]2CN3CCC2CC3)C[C@@]4([H])C5=C1C=CC=C5CCC4.[H]Cl



This page contains information about (R,R)-Palonosetron Hydrochloride Cas 135729-75-8 and its Drug Intermediates.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."